| abstract |
The present disclosure provides a therapeutically effective amount of IL-4/in combination with an agent that depletes a therapeutically effective amount of plasma cells (eg, an anti-BCMA/anti-CD3 bispecific antibody) to select a patient with allergy. Provided is a method for treating allergy comprising administering an IL-13 pathway inhibitor (eg, an anti-IL-4 receptor antibody or antigen-binding fragment thereof). In certain embodiments, a plasma cell ablation agent, e.g., an anti-BCMA/anti-CD3 bispecific antibody, ablates plasma cells comprising IgE+ plasma cells, and at the same time the IL-4/IL-13 pathway inhibitor is By preventing the production of new IgE+ plasma cells, allergen-specific IgE is eliminated in the patient. |